Despite the encouraging results of GLP-1/glucagon co-agonism in experimental models, different GLP-1 and glucagon co-agonists have shown various levels of efficacy and tolerability in people with obesity and/or T2D, in early phase clinical trials, which may be explained by the different ratio of GLP-1 to glucagon activity between the different molecules [65]
As our knowledge of GLP-1 biology advances and novel therapeutic innovations arise, these agents are expected to assume a progressively pivotal role in the management of metabolic disorders and their related complications, ultimately enhancing patient outcomes across various disease states
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
This leaves open the question that there may be some other primary effect that is yet to be determined, says Ard
Our program focuses on medically appropriate GLP-1 prescriptions based on clinical evaluation not automatic dose escalation
But, the idea is still controversial, and a large, nationwide trial of older adults, slated to test the hypothesis, hasn't started yet.
